Cagrilinitide: Mechanism of Action

Cagrilinitide (also referred to as cagrilintide; internal Novo Nordisk codes AM833 and NN9838) is an investigational, long-acting analog of human islet amyloid polypeptide (IAPP, amylin). It activates amylin receptors in the central nervous system to reduce food intake and body weight. This page describes the molecular targets, receptor pharmacology, intracellular signaling cascade, and neural circuit effectors through which cagrilinitide exerts its biological actions.

The Endogenous Template: Human Amylin (IAPP)

Human amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta-cells in response to nutrient ingestion. It suppresses glucagon secretion, slows gastric emptying, and reduces caloric intake by acting on amylin receptors in the brainstem and hypothalamus (PMID 29203236). These properties make amylin an attractive target for pharmacological analogs aimed at obesity management.

Native IAPP has two pharmacological liabilities that limit its therapeutic use: a very short circulatory half-life (minutes in plasma), and a propensity for amyloid aggregation. Pramlintide, the first approved amylin analog (Symlin), addresses aggregation through proline substitutions but still requires multiple daily injections due to its short half-life.

Cagrilinitide extends the paradigm: it combines amyloid-preventing amino acid substitutions with C-terminal fatty acid acylation via a linker, enabling albumin binding that dramatically prolongs the effective half-life to approximately one week and permits once-weekly subcutaneous dosing.

Primary Receptor Targets

Amylin Receptors Are Heterodimers

Amylin receptors are not single-subunit GPCRs. They are obligate heterodimeric complexes formed by the calcitonin receptor (CTR, gene: CALCR) and one of three receptor activity-modifying proteins (RAMPs 1, 2, or 3). The RAMP subunit confers amylin-binding selectivity on what would otherwise be a pure calcitonin receptor. The resulting complexes are named:

• AMY1: CTR + RAMP1
• AMY2: CTR + RAMP2
• AMY3: CTR + RAMP3

The structural basis for how RAMP subunits reshape the receptor extracellular domain to accommodate amylin-like peptides was clarified by cryo-EM structural work (PMID 35324283). RAMP1 and RAMP3 provide the predominant pharmacological activity relevant to cagrilinitide. AMY1(a) and AMY3(a) are the isoforms most highly expressed in the brain regions mediating appetite suppression.

Cagrilinitide Binding Profile

In radioligand competition and functional cAMP assays, cagrilinitide and its close structural relative NN1213 display high-affinity agonism at AMY1 and AMY3, with substantially lower potency at the homomeric CTR and at CGRP receptors (CLR/RAMP1) (PMID 38960379, PMID 38458773). This selectivity for amylin over calcitonin receptors is pharmacologically meaningful: CTR activation in bone mediates bone resorption-related effects, while amylin receptors in the brainstem and hypothalamus drive the metabolic actions.

The fatty acid chain on cagrilinitide enables reversible binding to albumin in plasma, reducing free-peptide concentration and thereby slowing receptor clearance rates. This pharmacokinetic trick is the same principle employed in semaglutide and insulin degludec.

Receptor Structure and Activation

The AMY receptor complex signals as a class B GPCR. Upon cagrilinitide binding:

1. The peptide inserts its C-terminus into the extracellular RAMP-modified binding cleft, engaging the receptor ectodomain.
2. The N-terminal helix of cagrilinitide inserts into the orthosteric transmembrane pocket of CTR.
3. This dual-point engagement drives conformational changes in the transmembrane helices of CTR.
4. Intracellular loops couple to heterotrimeric Gs protein.

The structural determinants of amylin vs. calcitonin selectivity reside largely in the RAMP subunit’s extracellular domain, which directly contacts the mid-region of the peptide (PMID 35324283).

Intracellular Signaling Cascade

Primary Pathway: Gs/cAMP/PKA

The dominant intracellular pathway downstream of AMY1/AMY3 activation is the Gs-adenylyl cyclase-cAMP axis. The sequence of events:

1. Gs activation. Cagrilinitide-bound CTR-RAMP complex recruits the alpha subunit of Gs, catalyzing GDP-to-GTP exchange.
2. Adenylyl cyclase stimulation. Gs-alpha activates membrane-bound adenylyl cyclase, converting ATP to cAMP.
3. PKA activation. Elevated cAMP binds the regulatory subunits of protein kinase A (PKA), releasing catalytic subunits.
4. Substrate phosphorylation. PKA phosphorylates downstream effectors including: the transcription factor CREB (Ser-133), voltage-gated ion channels, and regulators of neurotransmitter release.
5. CREB-mediated gene expression. pCREB drives transcription of immediate-early genes and neuropeptides that adjust neuronal excitability and circuit output (PMID 33166741).

RAMP expression level modulates the efficiency of Gs coupling: RAMP3-containing AMY3 receptors show subtly different G-protein coupling efficiency compared to RAMP1-containing AMY1, as demonstrated in heterologous expression systems (PMID 18599553).

Secondary Pathways

Beyond Gs/cAMP, class B GPCRs including amylin receptors engage additional signal branches:

• beta-arrestin recruitment mediates receptor internalization and endosomal signaling. Differential beta-arrestin coupling between AMY1 and AMY3 subtypes may contribute to distinct patterns of receptor desensitization.
• Gq/PLC activation has been reported at high agonist concentrations for some amylin receptor subtypes, leading to IP3 production and intracellular calcium mobilization. The functional relevance in neurons mediating satiety is under investigation.
• MAPK/ERK pathway is activated downstream of both cAMP and beta-arrestin in amylin receptor-expressing neurons, potentially contributing to longer-term synaptic plasticity effects.

Signaling Cascade Flowchart

flowchart TD
    A["Cagrilinitide\n(subcutaneous)"] --> B["Albumin binding\n(long-acting depot)"]
    B --> C["Systemic circulation"]
    C --> D1["AMY1(a) receptor\n(CTR + RAMP1)"]
    C --> D2["AMY3(a) receptor\n(CTR + RAMP3)"]
    D1 & D2 --> E["Gs protein activation\n(GDP → GTP exchange)"]
    E --> F["Adenylyl cyclase stimulation"]
    F --> G["↑ cAMP"]
    G --> H["PKA catalytic\nsubunit release"]
    H --> I1["CREB phosphorylation\n(Ser-133)"]
    H --> I2["Ion channel\nphosphorylation"]
    H --> I3["Synaptic protein\nphosphorylation"]
    I1 --> J["Gene transcription\n(neuropeptides, IEGs)"]
    I2 --> K["Altered neuronal\nexcitability"]
    J & K & I3 --> L["Reduced food intake\nSignal propagation"]

    D1 & D2 --> M["beta-arrestin recruitment"]
    M --> N["Receptor internalization\nERK signaling"]

    style A fill:#4a90d9,color:#fff
    style D1 fill:#7b68ee,color:#fff
    style D2 fill:#7b68ee,color:#fff
    style G fill:#f0a500,color:#fff
    style L fill:#2e8b57,color:#fff

Neural Circuit Effectors

Area Postrema and Nucleus Tractus Solitarius

The area postrema (AP) is a circumventricular organ at the floor of the fourth ventricle, positioned outside the blood-brain barrier. Neurons here are directly accessible to circulating peptides including cagrilinitide. The AP expresses high levels of AMY1 and AMY3 receptors. Activation of AP neurons by amylin agonists reduces meal size and meal frequency by relaying signals to the adjacent nucleus tractus solitarius (NTS) (PMID 29203236).

NTS neurons integrate AP input with vagal afferent signals from the gut and liver. They project to the parabrachial nucleus (PBN), which in turn communicates with the hypothalamus. This AP-NTS-PBN axis forms the ascending satiety relay.

Hypothalamic Arcuate Nucleus

The arcuate nucleus (ARC) of the hypothalamus contains two key neuronal populations relevant to cagrilinitide’s action:

• AgRP/NPY neurons: orexigenic; suppressed by amylin receptor activation.
• POMC/CART neurons: anorexigenic; activity may be enhanced by amylin signaling.

Amylin receptor-expressing neurons in the ARC receive input from brainstem satiety circuits and integrate leptin and insulin signals. Cagrilinitide engagement of ARC amylin receptors contributes to sustained reduction in energy intake beyond the acute meal-terminating effect mediated at the AP.

Complementarity with GLP-1 Receptor Signaling

CagriSema, the fixed-ratio co-formulation of cagrilinitide with semaglutide, achieves additive or potentially synergistic weight reduction by engaging two distinct receptor systems. GLP-1 receptors (GLP-1R) are expressed in the NTS, PVN, and peripheral tissues. Amylin receptors concentrate in the AP and ARC. The two receptor systems converge downstream at shared circuits governing energy homeostasis but use non-overlapping receptor populations, explaining why combining them produces greater weight loss than either alone (PMID 40544433, PMID 33166741).

Structural Features Enabling Long Activity

Cagrilinitide carries several engineered modifications relative to native IAPP:

The fatty acid modification is the key pharmacokinetic engineering element. Reversible albumin binding maintains a circulating depot of drug, releasing free peptide to activate receptors continuously over the dosing interval. This was refined from the NN1213 scaffold (PMID 38960379), which informed the structural template for cagrilinitide.

RAMP Isoform Selectivity and Tissue Distribution

RAMP1 is expressed broadly in the brain, including the AP, NTS, and hypothalamus, while RAMP3 is enriched in brainstem and kidney. RAMP2 expression in relevant appetite-regulating nuclei is low. Consequently, AMY1 (CTR+RAMP1) and AMY3 (CTR+RAMP3) account for the majority of cagrilinitide’s central anorexigenic activity.

Differences in RAMP subunit coupling efficiency affect downstream signaling magnitude: cells expressing higher RAMP3 levels relative to RAMP1 may generate distinct cAMP kinetics following the same receptor occupancy, potentially contributing to cell-type-specific responses to cagrilinitide across brain regions (PMID 34189795, PMID 18599553).

Key Primary Literature

This page describes molecular pharmacology based on published research. No clinical guidance, dosing recommendations, or health claims are intended or implied.

See also

More on Cagrilinitide:

• Cagrilinitide research overview
• Cagrilinitide: Clinical & preclinical evidence
• Cagrilinitide: Safety profile
• Cagrilinitide: Pharmacokinetics
• Cagrilinitide: Dose-response

Head-to-head comparisons:

• Semaglutide vs Cagrilinitide